Drug intelligence / Profile preview

CT-327

Development stage: Unknown
Lead developer: Cairn Therapeutics

Overview

CT-327 is a second-generation oncology drug candidate currently in the discovery and lead optimization phase, developed by Cairn Therapeutics. It is part of a pipeline of follow-on assets to the company's lead program, CT-262. As of early 2024, specific details regarding its mechanism of action, molecular target, and modality remain undisclosed by the developer, though it is being developed for the treatment of various cancers as part of Cairn's broader therapeutic platform.

Beyond the preview

Go deeper on CT-327.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT-327.

Explore the full profile